Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
1.
BMC Cancer ; 22(1): 652, 2022 Jun 13.
Article in English | MEDLINE | ID: mdl-35698215

ABSTRACT

BACKGROUND: Integrative medicine is used frequently alongside chemotherapy treatment in pediatric oncology, but little is known about the influence on toxicity. This German, multi-center, open-label, randomized controlled trial assessed the effects of complementary treatments on toxicity related to intensive-phase chemotherapy treatment in children aged 1-18 with the primary outcome of the toxicity sum score. Secondary outcomes were chemotherapy-related toxicity, overall and event-free survival after 5 years in study patients. METHODS: Intervention and control were given standard chemotherapy according to malignancy & tumor type. The intervention arm was provided with anthroposophic supportive treatment (AST); given as anthroposophic base medication (AMP), as a base medication for all patients and additional on-demand treatment tailored to the intervention malignancy groups. The control was given no AMP. The toxicity sum score (TSS) was assessed using NCI-CTC scales. RESULTS: Data of 288 patients could be analyzed. Analysis did not reveal any statistically significant differences between the AST and the control group for the primary endpoint or the toxicity measures (secondary endpoints). Furthermore, groups did not differ significantly in the five-year overall and event-free survival follow up. DISCUSSION: In this trial findings showed that AST was able to be safely administered in a clinical setting, although no beneficial effects of AST between group toxicity scores, overall or event-free survival were shown.


Subject(s)
Integrative Medicine , Neoplasms , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Child , Follow-Up Studies , Humans , Medical Oncology , Neoplasms/drug therapy , Neoplasms/etiology
2.
Pediatr Blood Cancer ; 57(4): 654-9, 2011 Oct.
Article in English | MEDLINE | ID: mdl-21584934

ABSTRACT

BACKGROUND: The treatment of childhood B-cell precursor acute lymphoblastic leukemia (ALL) after isolated extramedullary or late relapse is mostly based on chemotherapy or allogeneic transplantation. The aim of this study is to provocatively assess the role of purified autologous transplantation compared with best chemotherapy results in the same setting. PROCEDURE: We reported a series of 30 pediatric patients who underwent purified peripheral blood autologous transplantation for ALL in CR2, after isolated extramedullary (7), or late medullary (23) relapse from January 1997 and March 2004. Among 246 patients treated with chemotherapy within Berlin-Frankfurt-Münster relapse protocols during the same period, we found 103 controls who matched our 30 cases, according to site of relapse, CR1 duration, time elapsed in CR2, and period of relapse. RESULTS: Event-free survival and survival at 5 years after relapse were 73.3% (SE 8.1) and 86.5% (SE 8.2) for auto-transplanted cases and 40.0% (SE 9.7) and 62.5%(SE 9.6) for chemotherapy-treated controls (P-values: 0.012 and 0.025, respectively). The risk of relapse after auto-transplantation at 1 and 4 years was approximately half and one-fifth, respectively, of the same risk obtained with chemotherapy. CONCLUSIONS: This matched analysis showed an advantage of purified autologous transplantation compared with chemotherapy in low-risk relapsed ALL, possibly explained by the single-center effect, the myeloablation of total body irradiation, the documented low tumor burden at mobilization and the stem cell isolation procedure.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Peripheral Blood Stem Cell Transplantation , Precursor Cell Lymphoblastic Leukemia-Lymphoma/therapy , Adolescent , Child , Disease-Free Survival , Female , Humans , Kaplan-Meier Estimate , Male , Precursor Cell Lymphoblastic Leukemia-Lymphoma/mortality , Proportional Hazards Models , Recurrence , Transplantation, Autologous
3.
J Clin Oncol ; 27(3): 377-84, 2009 Jan 20.
Article in English | MEDLINE | ID: mdl-19064980

ABSTRACT

PURPOSE: Minimal residual disease (MRD) before allogeneic stem-cell transplantation was shown to predict outcome in children with relapsed acute lymphoblastic leukemia (ALL) in retrospective analysis. To verify this, the Acute Lymphoblastic Leukemia Relapse Berlin-Frankfurt-Münster (ALL-REZ BFM) Study Group conducted a prospective trial. PATIENTS AND METHODS: Between March 1999 and July 2005, 91 children with relapsed ALL treated according to the ALL-REZ BFM 96 or 2002 protocols and receiving stem-cell transplantation in >or= second remission were enrolled. MRD quantification was performed by real-time polymerase chain reaction using T-cell receptor and immunoglobulin gene rearrangements. RESULTS: Probability of event-free survival (pEFS) and cumulative incidence of relapse (CIR) in 45 patients with MRD >or= 10(-4) leukemic cells was 0.27 and 0.57 compared with 0.60 and 0.13 in 46 patients with MRD less than 10(-4) leukemic cells (EFS, P = .004; CIR, P < .001). Intermediate-risk patients (strategic group S1) with MRD >or= 10(-4) leukemic cells (n = 14) had a pEFS of 0.20 and CIR of 0.73, whereas patients with MRD less than 10(-4) leukemic cells (n = 21) had a pEFS of 0.68 and CIR of 0.09 (EFS, P = .020; CIR, P < .001). High-risk patients (S3/4, third complete remission) who received transplantation with an MRD load of less than 10(-4) leukemic cells (n = 25) showed a pEFS and CRI of 0.53 and 0.18, respectively. In contrast, pEFS and CRI were 0.30 and 0.50 in patients who received transplantation with an MRD load of >or= 10(-4) leukemic cells. Multivariate Cox regression analysis revealed MRD as the only independent parameter predictive for EFS (P = .006). CONCLUSION: MRD is an important predictor for post-transplantation outcome. As a result, new strategies with modified stem-cell transplantation procedures will be evaluated in ALL-BFM trials.


Subject(s)
Neoplasm, Residual/mortality , Precursor Cell Lymphoblastic Leukemia-Lymphoma/mortality , Stem Cell Transplantation , Adolescent , Child , Disease-Free Survival , Female , Humans , Male , Precursor Cell Lymphoblastic Leukemia-Lymphoma/pathology , Precursor Cell Lymphoblastic Leukemia-Lymphoma/therapy , Prognosis , Recurrence , Transplantation, Homologous
4.
Vet Dermatol ; 19(2): 77-87, 2008 Apr.
Article in English | MEDLINE | ID: mdl-18336424

ABSTRACT

Although spaying can result in qualitative hair coat changes in dogs, the influence of spaying on the hair growth cycle has never been described. The study aims were to examine the effect of spaying and gonadotropin-releasing hormone (GnRH) treatment on canine hair coat, cycle stages of hair follicles, plasma gonadotropin concentrations and mRNA transcription of luteinizing hormone (LH) and GnRH receptors in hair follicles. Fifteen female dogs were examined before and 1 year after spaying and 24 spayed dogs before and after GnRH treatment. Spaying resulted in increased plasma gonadotropin concentrations and increased anagen : telogen ratio of hair follicles, but only 20% of the dogs developed coat changes. No differences were found in mRNA transcription of LH and GnRH receptors. GnRH treatment resulted in reduced plasma gonadotropin concentrations and improvement of coat changes in 79% of patients. This was associated with an increase in catagen hair follicles without changes in the anagen : telogen ratio. The present study demonstrated that spaying had an effect on the anagen : telogen ratio of hair follicles. Spaying-induced coat changes did not correlate with the anagen : telogen ratio. GnRH treatment reduced gonadotropin concentrations and reversed coat changes in some dogs, but had no effect on the hair growth cycle other than increasing the number of catagen hair follicles. A weak positive correlation between the plasma LH concentration and the anagen : telogen ratio was noted; however, our data did not suggest a direct receptor-mediated hormonal effect on the hair follicle. The present study did not identify the pathomechanism of spaying-induced coat changes.


Subject(s)
Cell Division/drug effects , Gonadotropin-Releasing Hormone/physiology , Gonadotropin-Releasing Hormone/therapeutic use , Hair Follicle/cytology , Ovariectomy/veterinary , Animals , Dogs , Female , Gonadotropins/blood , Hair/growth & development , Hair Follicle/drug effects , Hair Follicle/growth & development , Luteinizing Hormone/blood , Ovariectomy/adverse effects , Ovariectomy/methods , Receptors, LHRH/metabolism , Skin Pigmentation
5.
Blood ; 110(12): 4022-9, 2007 Dec 01.
Article in English | MEDLINE | ID: mdl-17720883

ABSTRACT

This study investigates the extent of bone marrow (BM) involvement at diagnosis of apparent isolated extramedullary (AIEM) relapses of childhood acute lymphoblastic leukemia (ALL) and its relation to prognosis. Sixty-four children with first AIEM relapse treated in Germany, Czech Republic, or France were included. Real-time quantitative polymerase chain reaction using T-cell receptor and immunoglobulin gene rearrangements provided a sensitive measure of submicroscopic BM involvement, which was detectable at a level of 10(-4) or higher in 46 patients and less than 10(-4) in 11 patients, and was nondetectable (sensitivity: 10(-4)) in 7 patients. In the total cohort, the probability of event-free survival (pEFS) for children with BM involvement of 10(-4) or higher was 0.30 (0.09 +/- SE) versus 0.60 (+/- 0.12) for those with less than 10(-4) (P = .13). The cumulative incidence of subsequent relapse was 0.24 (+/- 0.01) for patients with BM involvement less than 10(-4) and 0.65 (+/- 0.01) for those with 10(-4) or higher (P = .012). Restricted to central nervous system (CNS) relapses, pEFS was 0.11 (+/- 0.09) for patients with BM involvement 10(-4) or higher and 0.63 (+/- 0.17) for those with less than 10(-4) (P = .053). CNS relapses were associated with a higher (> or = 10(-4): 80%) submicroscopic BM involvement than testicular relapses (> or = 10(-4): 57%, P = .08). In summary, we show marked heterogeneity of submicroscopic BM involvement at first AIEM relapse diagnosis in children with ALL, and demonstrate its possible prognostic relevance.


Subject(s)
Bone Marrow , Gene Rearrangement, B-Lymphocyte/genetics , Polymerase Chain Reaction , Precursor Cell Lymphoblastic Leukemia-Lymphoma/genetics , Receptors, Antigen, T-Cell/genetics , Adolescent , Bone Marrow/pathology , Child , Child, Preschool , Cohort Studies , Disease-Free Survival , Europe , Female , Humans , Infant , Infant, Newborn , Male , Precursor Cell Lymphoblastic Leukemia-Lymphoma/diagnosis , Precursor Cell Lymphoblastic Leukemia-Lymphoma/mortality , Precursor Cell Lymphoblastic Leukemia-Lymphoma/pathology , Recurrence , Retrospective Studies , Sensitivity and Specificity , Survival Rate
6.
Theriogenology ; 66(9): 2127-36, 2006 Dec.
Article in English | MEDLINE | ID: mdl-16876857

ABSTRACT

The pathophysiology of urinary incontinence due to spaying remains unknown. Incontinent bitches can be treated successfully with depot preparations of GnRH-analogues and there are differences in plasma gonadotropin levels between continent and incontinent spayed bitches. It is therefore assumed that the supraordinated hormones, GnRH, FSH, and/or LH, have an effect on the urodynamic parameters. In this study, the potential influence of these hormones on the lower urinary tract was investigated by measuring urethral pressure profiles and cystometry. Simultaneously, plasma concentrations in 10 spayed Beagle bitches were determined 5 weeks prior to and 8 weeks after treatment with the GnRH analogue leuprolide. Within 1 week of GnRH analogue administration, plasma FSH and LH levels decreased from 72.5 and 7.7 to 7.75 and 0.72ng/mL, respectively. These plasma gonadotropin levels correspond with those of intact bitches during anoestrus. Urethral pressure profiles indicated that the treatment had no significant effect on maximum urethral closure pressure, functional and total length of the urethra, or area of the closure pressure curve. The data obtained by cystometry regarding mean bladder threshold volume showed a significant increase from 109 to 172mL. The improvement in bladder function after the application of GnRH-application is presumably a direct effect of the GnRH as a relationship between the plasma gonadotropin levels and the urodynamic parameters could not demonstrated.


Subject(s)
Dog Diseases/blood , Dogs/physiology , Gonadotropin-Releasing Hormone/pharmacology , Urethra/physiology , Urinary Incontinence/veterinary , Animals , Dog Diseases/drug therapy , Dog Diseases/etiology , Dogs/blood , Female , Follicle Stimulating Hormone/blood , Gonadotropin-Releasing Hormone/analogs & derivatives , Leuprolide/pharmacology , Luteinizing Hormone/blood , Ovariectomy/adverse effects , Ovariectomy/veterinary , Pressure , Urinary Incontinence/blood , Urinary Incontinence/drug therapy , Urinary Incontinence/etiology
7.
Histochem Cell Biol ; 126(5): 527-35, 2006 Nov.
Article in English | MEDLINE | ID: mdl-16715322

ABSTRACT

It has been proposed that gonadotropins and/or gonadotropin releasing hormone (GnRH) could be involved in the pathophysiology of the side effects after spaying in bitches, such as urinary incontinence and an increased production of a woolly undercoat. In order to provide tools to investigate the role of these hormones in dogs we developed immunohistochemical techniques and real-time RT-PCR to study whether GnRH-, LH-, and FSH-receptors exist in canine skin and urinary bladder. Tissue samples from the skin of the flank region and the ventral midline of the urinary bladder from euthanised dogs were examined. We were able to quantify mRNA expression of GnRH-, FSH-, and LH-receptors in canine skin and bladder biopsies with a high primer efficacy. Immunohistochemical studies showed that GnRH-, FSH-, and LH-receptors are expressed in vessel walls, the epidermis, the hair follicle and in sebaceous and sweat glands in canine skin and in transitional epithelium, and smooth muscle tissue in the urinary bladder. Our data provide the fundamentals to examine the distribution of FSH-, LH-, and GnRH-receptors in canine skin and urinary bladder and to assess gene activity at the transcriptional level by real-time RT-PCR.


Subject(s)
Dog Diseases/etiology , Ovariectomy/adverse effects , RNA, Messenger/metabolism , Receptors, FSH/genetics , Receptors, LHRH/genetics , Receptors, LH/genetics , Skin/metabolism , Urinary Incontinence/veterinary , Animals , Dogs , Female , Immunohistochemistry , Male , Reverse Transcriptase Polymerase Chain Reaction , Urinary Bladder/metabolism , Urinary Incontinence/etiology
9.
J Am Vet Med Assoc ; 226(1): 73-6, 2005 Jan 01.
Article in English | MEDLINE | ID: mdl-15646576

ABSTRACT

OBJECTIVE: To evaluate long-term success of endoscopic injection of collagen into the urethral submucosa in female dogs with urinary incontinence caused by urethral sphincter incompetence. DESIGN: Retrospective study. ANIMALS: 40 incontinent female dogs. PROCEDURE: Medical records were reviewed for outcome and other results for dogs in which a cystoscope was passed into the urethra for deposition of 3 collagen deposits into the submucosa. RESULTS: 27 (68%) dogs were continent for 1 to 64 months (mean, 17 months) after the collagen injection. In another 10 dogs, incontinence improved and in 6 of these dogs, full continence was regained with administration of additional medication. In 3 dogs, incontinence was unchanged. As long as 12 months after injection, there was a deterioration in the initial result in 16 dogs, after which their condition stabilized. Mild and transient adverse effects developed in 6 (15%) dogs. CONCLUSIONS AND CLINICAL RELEVANCE: Long-term success of endoscopic injection of collagen was satisfactory. Relapse of incontinence might be caused by flattening of the collagen deposits rather than resorption of the collagen.


Subject(s)
Collagen/therapeutic use , Dog Diseases/therapy , Urinary Incontinence/veterinary , Urination Disorders/veterinary , Animals , Dogs , Female , Follow-Up Studies , Recurrence , Retrospective Studies , Treatment Outcome , Urethra/drug effects , Urethra/physiology , Urinary Incontinence/therapy , Urination Disorders/therapy , Urodynamics/drug effects , Urodynamics/physiology
SELECTION OF CITATIONS
SEARCH DETAIL
...